contd. a1

priority from U.S. Serial No. 60/035,826, filed January 8, 1997 and U.S. Serial No. 60/045,676, filed May 6, 1997, all of which are hereby expressly incorporated by reference.

**In the claims**:

Please cancel without prejudice claims 2-28, amend claim 1 and add new claims 29-41 as follows:

**Please amend claim 1 as follows**:

a2 pend C1

1. (Amended) A compound having the formula:

wherein B is a heterocyclic ring derived from a purine or pyrimidine moiety, and pharmaceutically acceptable salts, and prodrugs, thereof.

**Please add the following new claims**:

a3 C1 cont

29. (New) A compound having the formula:




wherein B is a heterocyclic ring derived from a purine or pyrimidine moiety, and pharmaceutically acceptable salts, and prodrugs, thereof.

30. (New) The compound of Claims 1 or 29, wherein B is selected from the group consisting of 6-aminopurine, 2,6-diaminopurine, 2-amino-6-cyclopropylaminopurine, 6-hydroxypurine, 2-amino-6-halo substituted purine, 2-amino-6-alkoxy substituted purine, 2-amino-6-hydroxypurine, 3-deazapurine, 7-deazapurine, 8-azapurine, cytosine, 5-halo

contd. A3

substituted cytosine, 5-halo substituted cytosine, 5-alkyl substituted cytosine, thymine, uracil and 6-azapyrimidine.

31. (New) The compound of Claims 1 or 29, wherein B is selected from the group consisting of adenin-$N^9$-yl, guanin-$N^9$-yl, cytosin-$N^1$-yl, 2,6-diaminopurine, 2-amino-6-cyclopropylaminopurin-$N^9$-yl and 2-amino-6-chloropurin-$N^9$-yl.

C1 cont

32. (New) An antiviral compound selected from the group consisting of syn-$N^9$-(2-hydroxymethylcyclopropylidenemethyl) adenine, syn-$N^9$ - (2 – hydromethylcyclopropylidenemethyl) guanine, syn-$N^1$-(2-hydroxymethylcyclopropylidenemethyl) cytosine, syn-2,6-diamino-$N^9$-(2-hydroxymethylcyclopropylidenemethyl) purine, syn-2-amino-6-cyclopropylamino-$N^9$-(2-hydroxymethylcyclopropylidenemethyl) purine and pharmaceutically acceptable salts, and prodrugs, thereof.

C1 cont B1

33. (New) An antiviral compound selected from the group consisting of methyl phenyl-phosphoro-L-alaninate of syn - $N^9$ - (2 - hydroxymethylcyclopropylidenemethyl) adenine, methyl phenyl-phosphoro-L-alaninate of anti-$N^2$-(2-hydroxymethylcyclopropylidenemethyl) and pharmaceutically acceptable salts, and prodrugs, thereof.

C1 cont

34. (New) A composition comprising a compound of Claims 1 and 29-33 and a pharmaceutically acceptable carrier.

35. (New) A method of treating mammals infected with a virus comprising the step of administering to the mammal an antiviral compound selected from the group consisting of the compounds of Claims 1 and 29-34.

36. (New) The method of Claim 35, wherein said mammal is a human.

37. (New) The method of Claim 35, wherein said virus is a human herpes virus.

38. (New) The method of Claim 35, wherein said virus is a human immunodeficiency virus.

39. (New) The method of Claim 35, wherein said virus is hepatitis B virus.

contd. A3

40. (New) The method of Claim 35, further comprising the step of administering an additional antiviral compound.

C1 cont

41. (New) The method of Claim 40, wherein the additional antiviral compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddI, ddC, d4T, and combinations thereof.